Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 201-758-7 | CAS number: 87-62-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Carcinogenicity
Administrative data
Description of key information
Carcinogenicity in vivo
Initial indications of a carcinogenic effect of 2,6-xylidine are available from a feeding study - however, in this case exposure via the inhalation path was also possible
Key value for chemical safety assessment
Justification for classification or non-classification
Based on these results, 2,6-xylidine is classified as a mutagenic carcinogen according to the EU and GHS criteria Cat. 3 and needs to be adequately labelled. In addition, the test substance is listed in the CLP Regulation No 1272-2008 on classification, labelling and packaging of substances and mixtures and classified as carcinogen cat.2.
Additional information
In a report of the National Toxicology Program (Montgomery et al., 1982) the carcinogenic effect following feeding with 2,6-xylidine was observed. The incidence of papillary adenomas and adenocarcinomas of the nasal cavity and for subcutaneous fibromas in male and female rats at the highest dose (3 g/kg feed) was significantly increased. This dose also led to a significant increase in the incidence of hepatomas in the female animals. 2 males and 2 females respectively of this dosage group showed rhabdomyosarcomas in the nasal cavities, a neoplastic lesion, which had not previously been described at this position in this species of rat. The high incidence of tumours in the nasal cavity in this study is remarkable for a feeding test. This could be an organotropic effect, as is known from some nitrosamines. This possibility is supported by the fact that 2,6-xylidine binds to the DNA of the nasal cavity mucous membrane after i.p. administration (Short et al., 1989b). Another possible explanation for the higher incidence of tumours in the nasal cavity is that the 2,6-xylidine in the feed is evaporated as a gas. In an examination by Jameson et al. (1984) it was shown that 7.2 % per day of the test substance is lost, and of this 70 – 80 % through evaporation from the feed. This effect leads to a not inconsiderable exposure via the inhalation path, which could explain the nasal cavity tumours found in this and the following studies. In a summary of 86 two year carcinogenicity studies the authors report on a feeding test, in which male and female CD1 rats were given 0, 300, 1000 or 3000 mg 2,6-xylidine per kg feed (no further information). Both the male-and-female animals showed papillary adenomas and adenocarcinomas in the nasal mucous membrane (Haseman et al., 1984).
Carcinogenicity: via oral route (target organ): respiratory: nose
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.